Enhancement of T cell recruitment and infiltration into tumours

Clinical and Experimental Immunology

Volumn 178, Issue 1, 2014, Pages 1-8

  Oelkrug, C ^a,b   Ramage, J M ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

Author keywords

Cancer; T cells; Tumour immunology

Indexed keywords

ANGIOGENESIS INHIBITOR; CHEMOKINE;

ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CELL MIGRATION; CHEMOTHERAPY; CYTOTOXIC T LYMPHOCYTE; ONCOLYTIC VIROTHERAPY; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG SCREENING; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84908155316     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12382     Document Type: Article

References (61)

1. Chew V, Chen J, Lee D et al. Chemokine-driven lymphocyte infiltration:an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 2012; 61:427-38.
2. Dahlin AM, Henriksson ML, Van GB et al. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol 2011; 24:671-82.
3. de la Cruz-Merino L, Henao CF, Vicente BD et al. Immune microenvironment in colorectal cancer: a new hallmark to change old paradigms. Clin Dev Immunol 2011; 2011:174149.
4. Dutoit V, Rubio-Godoy V, Dietrich PY et al. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res 2001; 61:5850-6.
5. Dutoit V, Guillaume P, Romero P, Cerottini JC, Valmori D. Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*. Cancer Immun 2002; 2:7-19.
6. Dutoit V, Rubio-Godoy V, Pittet MJ et al. Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans. J Exp Med 2002; 196:207-16.
7. Marelli-Berg FM, Frasca L, Weng L, Lombardi G, Lechler RI. Antigen recognition influences transendothelial migration of CD4+ T cells. J Immunol 1999; 162:696-703.
8. Marelli-Berg FM, Scott D, Bartok I, Peek E, Dyson J, Lechler RI. Activated murine endothelial cells have reduced immunogenicity for CD8+ T cells: a mechanism of immunoregulation? J Immunol 2000; 165:4182-9.
9. Marelli-Berg FM, James MJ, Dangerfield J et al. Cognate recognition of the endothelium induces HY-specific CD8+ T-lymphocyte transendothelial migration (diapedesis) in vivo. Blood 2004; 103:3111-6.
10. Marelli-Berg FM, Jarmin SJ. Antigen presentation by the endothelium:a green light for antigen-specific T cell trafficking? Immunol Lett 2004; 93:109-13.
11. Marelli-Berg FM, Cannella L, Dazzi F, Mirenda V. The highway code of T cell trafficking. J Pathol 2008; 214:179-89.
12. Marelli-Berg FM, Fu H, Vianello F, Tokoyoda K, Hamann A. Memory T-cell trafficking: new directions for busy commuters. Immunology 2010; 130:158-65.
13. Rao RM, Yang L, Garcia-Cardena G, Luscinskas FW. Endothelialdependent mechanisms of leukocyte recruitment to the vascular wall. Circ Res 2007; 101:234-47.
14. Weninger W, Manjunath N, von Andrian UH. Migration and differentiation of CD8+ T cells. Immunol Rev 2002; 186:221-33.
15. Vianello F, Olszak IT, Poznansky MC. Fugetaxis: active movement of leukocytes away from a chemokinetic agent. J Mol Med (Berl) 2005; 83:752-63.
16. Hamann A, Syrbe U. T-cell trafficking into sites of inflammation. Rheumatology (Oxf) 2000; 39:696-9.
17. Jaafar F, Righi E, Lindstrom V et al. Correlation of CXCL12 expression and FoxP3+ cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer. Am J Pathol 2009; 175:1525-35.
18. Molon B, Ugel S, Del PF et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 2011; 208:1949-62.
19. Lukacs NW, Berlin A, Schols D, Skerlj RT, Bridger GJ. AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am J Pathol 2002; 160:1353-60.
20. Ben-Baruch A. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis 2008; 25:345-56.
21. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9.
22. Bailey C, Negus R, Morris A et al. Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin Exp Metastasis 2007; 24:121-30.
23. Harlin H, Meng Y, Peterson AC et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69:3077-85.
24. Hong M, Puaux AL, Huang C et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res 2011; 71:6997-7009.
25. Hojo S, Koizumi K, Tsuneyama K et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 2007; 67:4725-31.
26. Poznansky MC, Olszak IT, Foxall R et al. Active movement of T cells away from a chemokine. Nat Med 2000; 6:543-8.
27. Kryczek I, Wei S, Keller E, Liu R, Zou W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 2007; 292:C987-C995.
28. Schimanski CC, Galle PR, Moehler M. Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors. World J Gastroenterol 2008; 14:4721-4.
29. Yoshitake N, Fukui H, Yamagishi H et al. Expression of SDF-1 alpha and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer. Br J Cancer 2008; 98:1682-9.
30. Popple A, Durrant LG, Spendlove I et al. The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer. Br J Cancer 2012; 106:1306-13.
31. Nardin A, Wong WC, Tow C et al. Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions. J Invest Dermatol 2011; 131:1896-905.
32. Soriano JL, Batista N, Santiesteban E et al. Metronomic cyclophosphamide and methotrexate chemotherapy combined with 1E10 anti-idiotype vaccine in metastatic breast cancer. Int J Breast Cancer 2011; 2011:710292.
33. Demaria S, Volm MD, Shapiro RL et al. Development of tumorinfiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 2001; 7:3025-30.
34. Antonia SJ, Mirza N, Fricke I et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006; 12:878-87.
35. Alizadeh D, Trad M, Hanke NT et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res 2014; 74:104-18. doi: 10.1158/0008-5472.CAN-13-1545.
36. Machiels JP1, Reilly RT, Emens LA et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factorsecreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001; 61:3689-97.
37. Martinet L, Garrido I, Filleron T et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res 2011; 71:5678-87.
38. Hindley JP, Jones E, Smart K et al. T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res 2012; 72:5473-82.
39. Weiss VL, Lee TH, Song H et al. Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. PLOS ONE 2012; 7:e31962.
40. Li X, Kostareli E, Suffner J, Garbi N, Hammerling GJ. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur J Immunol 2010; 40:3325-35.
41. Roselli M, Cereda V, di Bari MG et al. Effects of conventional therapeutic interventions on the number and function of regulatory T cells. Oncoimmunology 2013; 2:e27025.
42. Datta A, David R, Glennie S et al. Differential effects of immunosuppressive drugs on T-cell motility. Am J Transplant 2006; 6:2871-83.
43. Devaud C, John LB, Westwood JA, Darcy PK, Kershaw MH. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2013; 2:e25961.
44. Hodi FS1, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23. doi: 10.1056/NEJMoa1003466.
45. Huang RR, Jalil J, Economou JS et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res 2011; 17:4101-9.
46. Simpson TR, Li F, Montalvo-Ortiz W et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210:1695-710. doi: 10.1084/jem.20130579.
47. Peng W, Liu C, Xu C et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res 2012; 72:5209-18. doi:10.1158/0008-5472.CAN-12-1187.
48. Wu L, Yun Z, Tagawa T, Rey-McIntyre K, de Perrot M. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol Cancer Ther 2012; 11:1809-19.
49. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 2013; 210:1389-402.
50. Waitz R, Solomon SB, Petre EN et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res 2012; 72:430-9. doi: 10.1158/0008-5472.CAN-11-1782.
51. Dirkx AE, Oude Egbrink MG, Kuijpers MJ et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 2003; 63:2322-9.
52. Dirkx AE, Oude Egbrink MG, Castermans K et al. Antiangiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 2006; 20:621-30.
53. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70:6171-80.
54. Mulligan JK, Day TA, Gillespie MB, Rosenzweig SA, Young MR. Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions. Hum Immunol 2009; 70:375-82.
55. Wilmott JS, Scolyer RA, Long GV, Hersey P. Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. Oncoimmunology 2012; 1:997-9.
56. Liu C, Peng W, Xu C et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013; 19:393-403.
57. Wong NS, Buckman RA, Clemons M et al. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J Clin Oncol 2010; 28:723-30. doi:10.1200/JCO.2009.24.0143.
58. Lemay CG, Rintoul JL, Kus A et al. Harnessing oncolytic virusmediated antitumor immunity in an infected cell vaccine. Mol Ther 2012; 20:1791-9.
59. Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther 2014; 22:102-11.
60. Clinical trial: Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma, NCT01807182.
61. Huang RR1, Jalil J, Economou JS et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res 2011; 17:4101-9. doi: 10.1158/1078-0432.CCR-11-0407.